Christopher Chang, MD, PhD
Associate Director, GI Motility Program
Christopher Chang, MD, PhD is Associate Director of the Gastrointestinal Motility Program at Cedars-Sinai.
As a physician-scientist, his long term research and clinical interests center on gut microbes and their role in gastrointestinal (GI) health and disease. Dr. Chang’s clinic provides diagnostic and treatment options for patients who suffer from sequelae of GI infections, such as irritable bowel syndrome (IBS), small intestinal bacterial overgrowth and other gut motility disorders.
Board certified in internal medicine and gastroenterology, Dr. Chang has been awarded investigative grants from the National Institutes of Health and the American Gastroenterological Association. His research has focused on mechanisms of gut microbial pathogenesis and the impact of intestinal bacterial on immune responses, gut motility and other physiological processes. Most recently, he developed and is characterizing an animal model for post-infectious IBS to better understand the pathogenesis of IBS and identify therapeutic targets.
Dr. Chang has authored peer-reviewed research articles in numerous basic science and clinical investigative journals, and reviews papers for Journal of Bacteriology, Infection and Immunity, The IBD Journal, and other publications. He is a member of several scientific and professional organizations including the American Society for Microbiology, American Gastroenterological Association, and American College of Gastroenterology.
Dr. Chang earned his bachelor’s degree from Harvard University and his medical degree and doctorate from the University of California, San Francisco. He completed his residency and gastroenterology fellowship at University of California, Los Angeles (UCLA) Medical Center, and finished a post-doctoral research fellowship in the Department of Microbiology, Immunology, and Molecular Genetics at UCLA.